Research and Markets: Multiple Sclerosis Therapeutics Market Is Forecast To Grow At 12% Annually For the Next Seven Years to Reach $20.2 Billion By 2017

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/a36ce6/multiple_sclerosis) has announced the addition of GlobalData's new report "Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.

Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global Multiple Sclerosis therapeutics market and pipeline The report identifies the key trends shaping and driving the global Multiple Sclerosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Multiple Sclerosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The authors have estimated the global Multiple Sclerosis therapeutics market to be valued at $8.2 billion in 2009. It is expected to increase to $20.2 billion with a Compound Annual Growth Rate (CAGR) of 12% by 2017. There is a high unmet need in the current Multiple Sclerosis therapeutics market in terms of both safety and efficacy profile. New high potential drugs Multiple Sclerosis therapeutics are expected to come in the market after 2017.

Multiple Sclerosis Therapeutics Market is Forecasts to Show Modest Growth until 2017

The authors estimated the global Multiple Sclerosis (MS) therapeutics market to be worth $8.2 billion in 2009, and it is forecast to grow at 12% annually for the next seven years to reach $20.2 billion by 2017. This growth is primarily attributed to strong current treatment options as well as strong pipeline candidates. The growth will be further supported by the high incidence and prevalence of disease, and the high prescription rate of current marketed products. However, the barriers for the MS therapeutics market like low treatment-seeking rate, low diagnosis rate and availability of alternate options will cause a restriction in the markets size.

Competition in Multiple Sclerosis Therapeutics Market Continues to Become More Intense

The authors analyzed that Biogen Idec, Teva Pharmaceutical, Merck Serono and Bayer Schering Pharma remain the leading competitors in the global MS therapeutics market. Together, these companies accounted for approximately 99% of the global market share in 2009. Biogen Idec with Avonex and Tysabri remained the market leader with a share of approximately 30%. However, companies like Biogen Idec, Merck Serono, Sanofi-aventis, AstraZeneca and Glenmark with some of the most technologically advanced products in their pipeline portfolio, are expected to attract the most of their investors attention. The global MS therapeutics market has seen intense competition which is expected to further intensify in the coming years.

GlobalData, the industry analysis specialist, has released its new report, Multiple Sclerosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Multiple Sclerosis therapeutics market and pipeline The report identifies the key trends shaping and driving the global Multiple Sclerosis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Multiple Sclerosis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Multiple Sclerosis therapeutics market. Its scope includes:

  • Annualized global Multiple Sclerosis therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major classes such as nerve growth factor and doparmegenic neurons loss inhibitor
  • Analysis of the current and future competition in the global Multiple Sclerosis therapeutics market. Key market players covered are Novartis, Biogen Idec, Merck Serono and Sanofi Aventis.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Multiple Sclerosis therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Multiple Sclerosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Multiple Sclerosis market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Multiple Sclerosis market landscape? Identify, understand and capitalize.

Key Topics Covered:

  • 1 Summary
  • 2 Multiple Sclerosis Therapeutics: Introduction
  • 3 Multiple Sclerosis Therapeutics: Market Characterization Overview
  • 4 Multiple Sclerosis Therapeutics: Competitive Assessment
  • 5 Multiple Sclerosis Therapeutics: Pipeline Assessment
  • 6 Multiple Sclerosis Therapeutics: Implications for Future Market Competition
  • 7 Multiple Sclerosis Therapeutics: Future Players in Multiple Sclerosis Therapeutics Market
  • 8 Multiple Sclerosis Therapeutics: Appendix

Companies Mentioned:

  • Biogen Idec
  • Merck Serono
  • Sanofi-aventis
  • Novartis

For more information visit http://www.researchandmarkets.com/research/a36ce6/multiple_sclerosis

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716